6,500+
Total Number of Employees
35%
Employees involved in R&D and Quality
3
R&D Centers
200+
Clients Served
6
Innovators
Letter from our Founder
Dear Laurus Labs Family members & Stakeholders,
As we stand at the forefront of innovation and progress, I want to express my gratitude for the collective efforts that define our journey at Laurus Labs.
From pioneering pharmaceutical breakthroughs to championing sustainability and empowering communities, our commitment goes beyond business metrics. We are architects of positive change, creators of a legacy that extends beyond profits.
In the realm of healthcare, we are not just providers of medication; we are enablers of healing. Our endeavours reach beyond borders, making a tangible impact on individuals facing health challenges.
Our dedication to education echoes in the initiatives that nurture young minds, providing access to knowledge for a brighter future. In every action, we sow the seeds of growth and empowerment.
Environmental stewardship is ingrained in our DNA. Our green initiatives and pollution control programs reflect a profound understanding of our responsibility toward the planet.
As we move forward, let us continue to push boundaries, embrace innovation, and foster a culture where every effort contributes to a holistic legacy. Together, we are not just a company; we are architects of a future that prioritizes progress, compassion, and sustainable growth.
Thank you for being an integral part of this extraordinary journey.
Satyanarayana Chava
Founder & CEO
About Us
As a research-driven pharmaceutical manufacturing organization, Laurus Labs has been developing and assisting its client organizations to succeed in innovative medicines that globally enhance the health outcomes for patients.
Since our inception in 2005, we have been developing and manufacturing Active Pharmaceutical Ingredients (APIs) and Intermediates. We quickly scaled our pharmaceutical value chain by attaining a global leadership position in APIs, including anti-retroviral (ARV), Oncology, Cardiovascular, and Gastro therapeutics. Our position was strengthened by our backward-integration capability while remaining highly regulatory compliant across all operations.
Global Footprint
As our portfolio of pharmaceutical Ingredients & Finished Dosages was strengthened, in line with our vision, Laurus Labs extended its development and manufacturing solutions to multiple large pharmaceutical organizations.
Laurus Enclave, Plot Office 01 E, Bonangi (V), Parawada (M), Anakapalli (D) - 531 021, AP, India
Southgate Chambers, 37/39
Southgate Street, Winchester Hants SO23 9EH,
UK
C/o. Alfred E. Tiefenbacher Van-
Der-Smissen-Strasse 1 Hamburg,
DE, 22767
Van-der-Smissen-Strasse 1, 22767 Hamburg, Germany
Plot No:19,20,21; APSEZ, Gurajapalem, Atchutapuram,Visakhapatnam
Laurus Enclave, Plot Office 01 E, Bonangi (V), Parawada (M), Anakapalli (D) - 531 021, AP, India
Plot No: DS1, IKP Knowledge Park, Genome Valley, Turkapally, Medchal–Malkajgiri district ,
Telangana
As our portfolio of pharmaceutical Ingredients & Finished Dosages was strengthened, in line with our vision, Laurus Labs extended its development and manufacturing solutions to multiple large pharmaceutical organizations.
We emerged as one of the most trusted and largest pharmaceutical Contract Development & Manufacturing Organizations (CDMO) in India for both generics and the proprietary space.
While small-molecule chemistry is ingrained in our DNA, Laurus Labs recognizes the potential and differential benefits of large molecules, namely biologicals and biotechnology products, in the healthcare and nutritional space. We permeated this domain with the inception of Laurus Bio and continue the commitment by investing and collaborating in Cell and Gene therapies.
As a company, we are committed to conducting our business with utmost transparency, integrity, and responsibility towards our employees, society, customers, and all our stakeholders. We consciously and consistently strive to achieve our sustainable development goals, as showcased in our Environmental, Social, and Governance (ESG) focus and performance.
These compounding factors enable us to employ and retain the best talent while maintaining unabated trust from our customers and other stakeholders. Given that we operate in a highly regulated sector, we adopt a high-watermark approach for compliance to ensure that we exceed all requirements for applicable international standards.
Our Milestones
2006
- R&D was established
- Filed our first patent application
- Signed a term sheet with a leading Indian pharmaceutical company for oncology APIs
2007
- Commenced operations at the R&D Centre
- Executed manufacturing and services agreements with three multinational companies
- Established Unit 1
2008
- Filed our first-ever Drug Master File
- Commenced operations at Unit-I
- Supplied company's first product to the US
2009
- DSIR recognised our R&D Centre
- Commercialised four nutritional fine chemicals
- Launched first product in Europe
- Entered into a license agreement with an international organisation and a multinational company to manufacture and sell our products in the ARV segment
2010
- Received USFDA, TGA and UK MHRA certification for the Unit 1, Vishakhapatnam
2011
- Received USFDA and KFDA certification for our R&D Centre
- Received KFDA certification for Unit 1
2012
- Secured investment of INR 490 million from FIL Capital Management and FIP through primary investment and Secondary acquisition of Aptuit’s majority stake along with additional investments by one of our promoters
2013
- Crossed INR 10 billion in revenues
- Received WHO approval for Unit-I
2014
- Acquired 135 acres in Visakhapatnam for expansion
- Received an investment of INR 3000 million from Bluewater
- Commenced construction of Unit 2
- Incorporated Laurus Inc. in Delaware, US as a wholly-owned subsidiary
2015
- Commenced commercial operations at Unit 3, Visakhapatnam
- Acquired 27% stake in Sriam Labs Private Limited, Hyderabad
- Successful inspection by WHO, NIP Hungary and US FDA for Unit 1 and Unit 3 manufacturing sites
2016
- Successful USFDA inspection of the kilo-lab facility at our R&D Centre
- Received approval from BfArM Germany for Unit 2 at Vishakhapatnam
- Crossed INR 15 billion in revenues
- Filed first ANDA with the USFDA and first dossier with the WHO
2017
- Successful USFDA inspection of Unit 1, 2 & 3 API manufacturing facilities with no critical observations. (Unit 2 has no 483 observations)
- Successful WHO inspection of Units 1, 2 & 3
- Successful BGV Hamburg (German Regulatory Authority) inspection of Unit 2 (FDF) with no critical or major observations
2018
- Crossed INR 20 billion of revenue. Commenced commercial operations from Unit 4.
- Incorporated a subsidiary in Germany.
- Unit 2-Formulations, inspected by USFDA with Zero 483 observations.
- Launched maiden FDF product Tenofovir in USA, Canada and emerging markets.
- Certified as Great Place to Work for the year 2018.
2019
- Unit 6 – EIR Received from USFDA
- Entered into Strategic partnership with Global Fund for 3.5 years.
- Executed a major tender order and delivered ahead of schedule
- Executed highest on-time delivery in FDF orders.
- Maiden EIR received for Unit 4
2020
- Incorporated Laurus Synthesis Pvt. Ltd
- Acquired assets of an API Unit in Vizag
- Acquired Aspen’s South Africa Subsidiary – Laurus Generics SA(PTY) Limited
2021
- Incorporated Laurus Ingredients Pvt. Ltd. A Wholly Owned step down subsidiary of Laurus Synthesis Pvt. Ltd.
- Acquisition of 72.55% stake in Richcore Life Sciences Pvt Ltd (Laurus Bio)
- Laurus Labs acquires substantial minority stake in a CAR-T cell therapy company - ImmunoACT
2022
- Crossed INR 48 billion of revenue
- Incorporated Laurus Synthesis Pvt. Ltd & acquired assets of an API Unit in Vizag
- Acquired Aspen’s South Africa Subsidiary – Laurus Generics SA(PTY) Limited
- Laurus Synthesis Inc USA is merged with Laurus Generics Inc USA.
- Crossed INR 16 billion FDF Sales
7,500 KL
Reactor Volumes
10 billion
tabs/caps Formulations (OSD)
75+
Launches across Drug Product (DP) & Drug Substance (DS)
975+
Quality Audits
10
Manufacturing Sites
208
Patents Granted
6,041 cr
Revenue; 22% Growth
1,594 cr
26% EBITDA Margin
990 cr
Capex; 16% of Revenues
23%
ROCE
790 cr
Net Profit
3.5%
R&D Spend as a % of Sales